Crinetics Pharmaceuticals (CRNX) Net Equity Issued and Repurchased (2017 - 2026)

Crinetics Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $380.5 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $380.5 million in Q1 2026; TTM through Mar 2026 was $380.5 million, a 35.71% decrease from a year earlier, with the FY2024 full-year figure at $985.0 million, up 166.54% from the prior year.
• Net Equity Issued and Repurchased declined to $380.5 million in Q1 2026 per CRNX's latest filing, from $543.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $543.5 million in Q4 2024 and bottomed at -$13000.0 in Q3 2022.
• The 4-year median for Net Equity Issued and Repurchased is $188.6 million (2023), against an average of $215.6 million.
• Across the five-year window, Net Equity Issued and Repurchased tumbled 100.09% in 2022 and soared 2530538.46% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$13000.0 in 2022, then surged by 225430.77% to $29.3 million in 2023, then jumped by 1755.5% to $543.5 million in 2024, then declined by 29.99% to $380.5 million in 2026.
• Per Business Quant, the three latest CRNX Net Equity Issued and Repurchased figures stand at $380.5 million (Q1 2026), $543.5 million (Q4 2024), and $48.3 million (Q3 2024).